查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853209

按产品类型、适应症、给药途径和最终用户分類的孕酮市场—2025-2032年全球预测

Progesterone Market by Product Type, Indication, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，黄体素市场规模将达到 41.6 亿美元，复合年增长率为 13.84%。

关键市场统计数据
基准年 2024 14.7亿美元
预计年份：2025年 16.8亿美元
预测年份 2032 41.6亿美元
复合年增长率 (%) 13.84%

全面介绍孕酮的临床重要性、其製剂演变、法规环境及其对治疗及商业策略的影响

孕酮仍然是生殖健康和治疗管理中的关键激素，其临床应用范围广泛，包括避孕、不孕症治疗和荷尔蒙补充疗法。孕酮在调节月经週期、支持怀孕和调节子宫内膜反应方面的生化作用，使其在临床上持续受到重视，并推动了製剂科学和给药途径优化方面的研究。

合成类似物、给药系统和伴随诊断的最新进展正在重塑临床医生开具孕激素类药物处方的方式以及患者对此类药物的依从性。同时，不断变化的监管要求和日益严格的药物安全检测警戒审查迫使生产商和临床相关人员优先考虑安全性数据、生物等效性策略和上市后监测。从传统的片剂给药方案转向多种剂型，例如经皮和阴道製剂，既反映了患者偏好的趋势，也体现了降低全身暴露和实现局部靶向作用的需求。

综上所述，这些动态因素共同描绘出一幅复杂的图景，涉及治疗合理性、製剂创新和医疗保健系统采纳三者之间的交汇点。引言部分深入探讨了变革性转变、政策影响、细分市场细微差别、区域差异、企业策略，并为引领产业领导者应对这一不断变化的环境提供了切实可行的建议。

不断发展的临床实践、监管重点、给药创新和生产策略如何重新定义孕酮生态系统的价值创造

黄体素市场格局的演变不仅体现在产品的渐进式更新上，更体现在临床、生产和商业模式的系统性变革。药物传递技术的进步推动了局部阴道给药疗法在子宫内膜保护和生育支持方面的应用，而注射和皮下给药方案也在不断改进，以实现更可预测的药物动力学和更高的患者便利性。

监管政策的改变也在推动变革。监管机构越来越关注真实世界安全性数据和疗效比较，鼓励企业投资于可靠的上市后证据，并设计能够捕捉生活品质结果（除传统终点外）的研究。精准医疗运动与生殖健康领域交会融合，临床医生力求根据患者的表型和治疗目标定制孕激素治疗方案，这反过来又会影响处方决策和用药模式。

在商业层面，临床服务提供者与製造商之间的策略联盟日益普遍，从而实现了整合诊断、治疗和监测的综合护理路径。此外，生产策略也在不断演进，优先考虑灵活的生产能力和地理分散，以降低供应中断的风险。总而言之，这些变革性的变化正在重新定义孕酮生态系统中价值的创造和获取方式，并对敏捷性、实证实践和以患者为中心的设计提出了新的要求。

针对关税变化对孕酮供应链和采购动态的累积营运和合约影响，制定预测策略

2025年关税调整和贸易政策更新的前景将迫使製造商、经销商和医疗保健系统重新评估与孕酮成品采购和生产相关的供应链韧性和成本结构。关税调整可能会影响原料药的采购、进口製剂成分和成品出货，进而对筹资策略和合约谈判产生连锁反应。

为因应贸易格局的变化，相关人员在评估替代供应路线、近岸外包方案以及策略性库存，以确保医疗服务的连续性。采购团队正在协商更长期的供应协议，并针对关键中间体探索多供应商采购安排，以减少对单一国家供应商的依赖。同时，随着企业筹资策略的调整，品质保证和合规性问题仍然至关重要，因为更换供应商地区通常需要额外的审核和监管申报。

此外，支付方和医疗服务提供方网路正在将潜在的成本波动纳入处方管理和采购决策中。诊所和医院正与生产商合作，了解关税对定价和报销的影响，而居家医疗提供者则在探索应对或缓解成本上涨的营运方法。因此，与关税相关的政策变化所带来的累积影响将不仅限于单位经济效益，还将波及整个孕酮价值链的合约条款、库存管理和长期策略规划。

详细的市场细分揭示了产品、适应症、给药方法和最终用户方面的差异，这些差异驱动着临床差异化、证据需求和商业性定位。

透过精细化的市场细分，我们可以清楚地了解产品类型、适应症、给药途径和最终用户等方面的需求驱动因素和创新机会。依产品类型划分，市场涵盖天然和合成孕激素，其中合成孕激素可进一步细分为Medroxyprogesterone和炔诺酮。这种区分会影响製剂选择、专利格局和临床医生的偏好，因为天然和合成分子在药理学和生产过程方面存在差异。以适应症划分，市场用途包括避孕、促排卵药物和荷尔蒙补充疗法。避孕药类别进一步细分为口服复方避孕药和单孕激素避孕药，促排卵药物类别细分为辅助生殖技术和促排卵药物，荷尔蒙补充疗法细分为子宫内膜保护和闭经管理。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 随着女性寻求天然荷尔蒙疗法，对生物同源孕酮乳膏的需求不断增长。
  • 成本效益推动非专利微粒化孕酮胶囊在新兴市场扩张
  • 临床试验正在研究皮下注射孕酮作为阴道给药的替代方案。
  • 越来越多的研究关注孕酮在治疗创伤性脑损伤的神经保护作用
  • 缓释性孕激素植入在长期荷尔蒙管理的应用日益广泛
  • 定制孕激素处方笺药生产的配製药房面临日益严格的监管审查
  • 将孕酮水平监测整合到全球数位生殖追踪平台中
  • 透过生技公司和学术界的合作开发新型孕酮受体调变器

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的黄体素市场

  • 天然孕酮
  • 合成黄体素
  • Medroxyprogesterone
  • 炔诺酮

9. 依适应症分類的黄体素市场

  • 避孕药
    • 复方口服避孕药
    • 仅含黄体素的避孕药
  • 不孕症治疗
    • 辅助生殖技术
    • 诱导排卵
  • 荷尔蒙补充疗法
    • 子宫内膜保护
    • 更年期管理

10. 依给药途径分類的黄体素市场

  • 注射
    • 肌肉内注射
    • 皮下注射
  • 口服
  • 经皮
  • 阴道
    • 阴道凝胶
    • 阴道栓剂
    • 阴道片

第十一章 依最终用户分類的黄体素市场

  • 诊所
  • 家庭医疗保健
  • 医院

第十二章 各地区孕酮市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的黄体素市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国孕酮市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • BASF SE
    • Merck KGaA
    • Balchem Corporation
    • Strides Pharma Science Limited
    • Gnosis SpA
    • Caldic BV
    • Laboratoires Besins International
    • Ferring International Center SA
    • Teva Pharmaceutical Industries Ltd
    • Pharmascience Inc.
Product Code: MRR-E3708867712D

The Progesterone Market is projected to grow by USD 4.16 billion at a CAGR of 13.84% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.47 billion
Estimated Year [2025] USD 1.68 billion
Forecast Year [2032] USD 4.16 billion
CAGR (%) 13.84%

Comprehensive orientation to progesterone's clinical importance, formulation evolution, regulatory environment, and implications for therapeutic and commercial strategy

Progesterone remains a cornerstone hormone in reproductive health and therapeutic management, with a breadth of clinical applications that span contraception, fertility support, and hormone replacement therapy. Its biochemical role in regulating menstrual cycles, supporting gestation, and modulating endometrial response underpins sustained clinical demand and continued scientific interest in formulation science and route-of-administration optimization.

Recent advances in synthetic analogues, delivery systems, and companion diagnostics have reshaped the way clinicians prescribe and patients adhere to progesterone-based regimens. Concurrently, evolving regulatory expectations and heightened scrutiny around pharmacovigilance have compelled manufacturers and clinical stakeholders to prioritize safety data, bioequivalence strategies, and post-market surveillance. Transitioning from traditional tablet regimens toward diversified formats such as transdermal systems and vaginal formulations reflects both patient preference trends and the push for targeted local effects with reduced systemic exposure.

Taken together, these dynamics underscore a complex landscape in which therapeutic rationale, formulation innovation, and health-system adoption converge. The introduction sets the stage for a detailed examination of transformative shifts, policy impacts, segmentation nuances, regional differentials, corporate strategies, and practical recommendations for industry leaders seeking to navigate this evolving environment.

How evolving clinical practice, regulatory emphasis, delivery innovations, and manufacturing strategies are redefining value creation across the progesterone ecosystem

The progesterone landscape is shifting in ways that extend beyond incremental product updates and instead reflect systemic transformation across clinical practice, manufacturing, and commercial models. Advances in drug delivery technology have enabled localized vaginal therapies to gain traction for endometrial protection and fertility support, while injectable and subcutaneous options are being refined for more predictable pharmacokinetics and improved patient convenience.

Regulatory shifts are also driving change. Agencies are increasingly focused on real-world safety data and comparative effectiveness, prompting companies to invest in robust post-market evidence generation and to design trials that capture quality-of-life outcomes alongside traditional endpoints. Precision medicine trends intersect with reproductive health as clinicians seek to tailor progesterone therapies according to patient phenotypes and treatment goals, which in turn influences formulary decisions and prescribing patterns.

On the commercial front, strategic partnerships between clinical service providers and manufacturers are becoming more common, enabling integrated care pathways that bundle diagnostics, therapy, and monitoring. Additionally, manufacturing strategies are evolving to prioritize flexible capacity and geographic diversification to mitigate supply disruption risks. Taken together, these transformative shifts are redefining how value is created and captured in the progesterone ecosystem and setting new expectations for agility, evidence generation, and patient-centric design.

Anticipatory strategies for managing the cumulative operational and contractual effects of tariff changes on progesterone supply chains and procurement dynamics

The prospect of tariff changes and trade policy updates in 2025 compels manufacturers, distributors, and health systems to reassess supply chain resilience and cost structures associated with progesterone sourcing and finished-dose production. Tariff adjustments can affect active pharmaceutical ingredient procurement, imported formulation components, and finished product shipments, creating cascading implications for sourcing strategies and contract negotiations.

In anticipation of trade shifts, stakeholders are evaluating alternative supply routes, nearshoring options, and strategic stockholding to maintain continuity of care. Procurement teams are negotiating longer-term supply agreements and exploring multi-sourcing arrangements for critical intermediates to reduce dependence on single-country suppliers. Meanwhile, quality assurance and regulatory compliance considerations remain paramount as firms alter sourcing strategies, since changes in supplier geography often necessitate additional audits and regulatory filings.

Moreover, payer and provider networks are factoring potential cost variability into formulary management and purchasing decisions. Clinics and hospitals are engaging with manufacturers to understand the implications of customs duties on pricing and reimbursement dynamics, while home healthcare providers are exploring operational levers to absorb or mitigate incremental costs. The cumulative effect of tariff-related policy shifts is therefore not limited to unit economics; it influences contractual terms, inventory management, and longer-term strategic planning across the progesterone value chain.

Detailed segmentation reveals product, indication, delivery, and end-user distinctions that drive clinical differentiation, evidence needs, and commercial positioning

A granular segmentation lens clarifies demand drivers and innovation opportunities across product types, indications, delivery pathways, and end users. Based on product type, the market encompasses both Natural Progesterone and Synthetic Progesterone, with Synthetic Progesterone further differentiated into Medroxyprogesterone Acetate and Norethisterone; this differentiation has implications for formulation choices, patent landscapes, and clinician preference, as natural and synthetic molecules present distinct pharmacology and manufacturing considerations. Based on indication, applications span Contraceptives, Fertility Treatments, and Hormone Replacement Therapy, where the Contraceptives category further subdivides into Combined Oral Contraceptive and Progestin-Only Pill, the Fertility Treatments segment differentiates into Assisted Reproductive Technology and Ovulation Induction, and Hormone Replacement Therapy is parsed into Endometrial Protection and Menopause Management; each sub-indication carries unique clinical endpoints, adherence challenges, and payer considerations that influence product positioning and evidence needs.

Based on route of administration, delivery formats include Injectable, Oral, Transdermal, and Vaginal, with the Injectable option further classified into Intramuscular Injection and Subcutaneous Injection and Vaginal delivery explored through Vaginal Gel, Vaginal Suppository, and Vaginal Tablet; route-specific preferences affect bioavailability profiles, manufacturing complexity, and patient adherence outcomes. Based on end user, the landscape comprises Clinics, Home Healthcare, and Hospitals, and each setting imposes different procurement processes, cold-chain or handling requirements, and interactions with prescribers and payers. Integrating these segmentation dimensions reveals areas of unmet need where formulation innovation, targeted clinical evidence, and tailored commercial strategies can unlock value and improve patient experience.

Region-specific regulatory, infrastructure, and payer dynamics that determine access pathways, distribution complexity, and strategic priorities across global markets

Regional dynamics shape access, regulatory navigation, and market priorities in ways that are essential for strategic planning. In the Americas, health-system consolidation, payer-driven formulary management, and a high degree of clinical guideline uptake influence procurement cycles and evidence expectations; private and public payers closely evaluate therapeutic value and often require comparative data or cost-effectiveness rationale for new or reformulated progesterone products. In Europe, Middle East & Africa, a heterogeneous mix of regulatory frameworks and reimbursement environments creates both challenges and opportunities: centralized approvals in some jurisdictions coexist with country-level access hurdles that require locally tailored dossiers and stakeholder engagement strategies. Meanwhile, in parts of Africa and the Middle East, supply chain fragility and infrastructure constraints underline the need for robust distribution partnerships and simplified delivery formats.

In the Asia-Pacific region, rapid growth in clinical services, expanding fertility-care infrastructure, and progressive regulatory reform in several markets are driving demand for diverse progesterone formulations. The region also exhibits strong manufacturing capabilities for active ingredients and generics, presenting opportunities for contract manufacturing and cost-competitive production. Across all regions, differences in cultural attitudes toward reproductive health, prescribing norms, and patient preferences necessitate nuanced market-entry plans and region-specific evidence generation, while cross-regional lessons on technology adoption and care models can inform scalable strategies.

How corporate strategies, partnerships, and manufacturing agility are shaping competitive positioning and enabling evidence-driven differentiation in progesterone portfolios

Corporate strategies in the progesterone sector are increasingly characterized by a blend of innovation investment, partnership formation, and manufacturing agility. Innovator companies continue to advance novel formulations, delivery systems, and combination therapies to address unmet clinical needs and differentiate on patient-centric outcomes. At the same time, generic manufacturers and contract development and manufacturing organizations are optimizing production efficiencies and pursuing regulatory pathways that demonstrate bioequivalence while minimizing time-to-market.

Strategic collaborations between pharmaceutical firms, specialty compounding providers, and clinical service networks are becoming more prevalent as stakeholders seek to deliver integrated care solutions that include diagnostics, therapeutics, and adherence support. Companies are also investing in real-world evidence capabilities and pharmacovigilance infrastructure to meet heightened regulatory expectations and to support payer negotiations. In parallel, some firms are focusing on geographic diversification of manufacturing and warehousing to reduce trade-related risk and to comply with localized regulatory requirements. Competitive differentiation increasingly depends on a company's ability to combine clinical credibility, supply reliability, and commercial agility, while aligning product portfolios with emerging treatment pathways and provider workflows.

Actionable strategic imperatives for executives to align innovation, regulatory readiness, and supply resilience with targeted commercialization and partnership models

Industry leaders should pursue integrated approaches that align research investment, regulatory strategy, and supply-chain resilience to capture opportunities while mitigating risk. First, prioritize formulation innovation targeted at clinically meaningful benefits such as improved local delivery, reduced systemic side effects, and enhanced adherence, and align clinical development programs to generate the specific endpoints payers and providers value. Second, strengthen regulatory and market-access functions to anticipate evolving requirements for real-world evidence and post-market safety monitoring, ensuring dossiers are designed to support reimbursement discussions across heterogeneous jurisdictions.

Third, invest in flexible manufacturing and diversified sourcing strategies to reduce exposure to trade disruptions and to shorten lead times for product introduction. Fourth, explore strategic partnerships with clinics, hospitals, and home-care providers to integrate therapy delivery with diagnostics and patient support services, thereby improving uptake and clinical outcomes. Fifth, develop targeted commercialization plans that reflect segmentation realities-product type, indication, route of administration, and end-user requirements-while applying regional insights to adapt messaging and evidence packages. By executing these coordinated actions, leaders can better navigate regulatory change, optimize value capture, and accelerate adoption across care settings.

Mixed-method research combining stakeholder interviews, regulatory and clinical literature synthesis, patent review, and scenario analysis to ensure rigorous and actionable insights

The research approach combined primary qualitative engagement with secondary synthesis to derive robust, practice-oriented findings. Primary research included interviews with clinicians across obstetrics, gynecology, reproductive endocrinology, and hospital pharmacy to capture clinical decision drivers and patient adherence considerations, supplemented by discussions with procurement leaders and regulatory affairs specialists to understand access barriers and submission requirements. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical guideline statements, and patent and safety databases to triangulate clinical efficacy, safety trends, and intellectual property dynamics.

Analytical methods involved cross-validation of interview insights with document-based evidence, thematic coding to identify recurring commercial and clinical themes, and scenario analysis to explore supply-chain and policy contingencies. Quality control measures included source verification, expert peer review of interpretation, and adherence to transparent documentation practices to ensure reproducibility of findings. Wherever possible, regional granularity was derived by mapping regulatory frameworks and provider infrastructures against clinical practice patterns to produce actionable, jurisdiction-aware recommendations.

Synthesis of clinical relevance, delivery innovation, regulatory pressure, and operational readiness that determines competitive success across the progesterone value chain

The evolving progesterone landscape presents simultaneous opportunities and responsibilities for innovators, manufacturers, and care providers. Therapeutic relevance across contraception, fertility care, and menopause management ensures continued clinical focus, while advancements in delivery technology and evidence expectations create pathways for meaningful differentiation. At the same time, trade policy shifts, regulatory intensification around safety and real-world evidence, and regional heterogeneity in access mechanisms require deliberate strategic planning.

Synthesis of segmentation, regional, and corporate dynamics highlights that successful offerings will integrate clear clinical value, supply reliability, and adaptable commercialization strategies that reflect end-user realities. Companies that invest in targeted formulation work, evidence generation aligned to payer needs, and manufacturing flexibility will be positioned to respond to clinician preferences and patient expectations. Ultimately, the clinical utility of progesterone must be matched by commercial models and operational capabilities that deliver consistent access, transparent value propositions, and measurable outcomes in diverse care environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for bioidentical progesterone creams driven by women seeking natural hormone therapy
  • 5.2. Expansion of generic micronized progesterone capsules in emerging markets due to cost benefits
  • 5.3. Clinical trials exploring subcutaneous progesterone injection as an alternative to vaginal administration
  • 5.4. Growing research into progesterone's neuroprotective role for traumatic brain injury treatment
  • 5.5. Increasing adoption of sustained-release progesterone implants for long-term hormone management
  • 5.6. Regulatory scrutiny intensifies on compounding pharmacies producing custom progesterone formulations
  • 5.7. Integration of progesterone level monitoring into digital fertility tracking platforms worldwide
  • 5.8. Collaborations between biotech firms and academia to develop novel progesterone receptor modulators

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Progesterone Market, by Product Type

  • 8.1. Natural Progesterone
  • 8.2. Synthetic Progesterone
    • 8.2.1. Medroxyprogesterone Acetate
    • 8.2.2. Norethisterone

9. Progesterone Market, by Indication

  • 9.1. Contraceptives
    • 9.1.1. Combined Oral Contraceptive
    • 9.1.2. Progestin-Only Pill
  • 9.2. Fertility Treatments
    • 9.2.1. Assisted Reproductive Technology
    • 9.2.2. Ovulation Induction
  • 9.3. Hormone Replacement Therapy
    • 9.3.1. Endometrial Protection
    • 9.3.2. Menopause Management

10. Progesterone Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular Injection
    • 10.1.2. Subcutaneous Injection
  • 10.2. Oral
  • 10.3. Transdermal
  • 10.4. Vaginal
    • 10.4.1. Vaginal Gel
    • 10.4.2. Vaginal Suppository
    • 10.4.3. Vaginal Tablet

11. Progesterone Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Progesterone Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Progesterone Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Progesterone Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. BASF SE
    • 15.3.2. Merck KGaA
    • 15.3.3. Balchem Corporation
    • 15.3.4. Strides Pharma Science Limited
    • 15.3.5. Gnosis S.p.A.
    • 15.3.6. Caldic B.V.
    • 15.3.7. Laboratoires Besins International
    • 15.3.8. Ferring International Center S.A.
    • 15.3.9. Teva Pharmaceutical Industries Ltd
    • 15.3.10. Pharmascience Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PROGESTERONE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PROGESTERONE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PROGESTERONE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PROGESTERONE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PROGESTERONE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PROGESTERONE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PROGESTERONE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS PROGESTERONE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS PROGESTERONE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS PROGESTERONE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS PROGESTERONE MARKET SIZE, BY VAGINAL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS PROGESTERONE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS PROGESTERONE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA PROGESTERONE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA PROGESTERONE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE PROGESTERONE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE PROGESTERONE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE PROGESTERONE MARKET SIZE, BY VAGINAL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE PROGESTERONE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE PROGESTERONE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST PROGESTERONE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST PROGESTERONE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST PROGESTERONE MARKET SIZE, BY VAGINAL, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST PROGESTERONE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST PROGESTERONE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 341. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 342. ASIA-PACIFIC PROGESTERONE